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Context. Does octreotide reduce vomiting in cancer-associated bowel obstruction?
Objectives. To evaluate the net effect of adding octreotide or placebo to standardized therapies on the number of days free
of vomiting for populations presenting with vomiting and inoperable bowel obstruction secondary to cancer or its treatment.
Methods. Twelve services enrolled people with advanced cancer presenting with vomiting secondary to bowel obstruction
where surgery or anti-cancer therapies were not indicated immediately. In a double-blind study, participants were randomized
to placebo or octreotide (600 mg/24 hours by infusion). Both arms received standardized supportive therapy (infusion of
ranitidine [200 mg/24 hours], dexamethasone [8 mg/24 hours], and parenteral hydration [10e20 mL/kg/24 hours]). The
primary outcome was patient-reported days free of vomiting at 72 hours.
Results. In a study that recruited to the numbers identified in its power calculation, 87 participants provided data at
72 hours (45, octreotide arm). Seventeen people (octreotide) and 14 (placebo) were free of vomiting for 72 hours (P ¼ 0.67).
Mean days free of vomiting were 1.87 (SD 1.10; octreotide) and 1.69 (SD 1.15; placebo; P ¼ 0.47). An adjusted multivariate
regression of the incidence of vomiting over the study showed a reduced number of episodes of vomiting in the octreotide
group (incidence rate ratio ¼ 0.40; 95% CI: 0.19e0.86; P ¼ 0.019); however, people in the octreotide arm were 2.02 times
more likely to be administered hyoscine butylbromide (P ¼ 0.004), potentially reflecting increased colicky pain.
Conclusion. Although there was no reduction in the number of days free of vomiting, the multivariate analysis suggests that
further study of somatostatin analogues in this setting is warranted. J Pain Symptom Manage 2015;49:814e821.  2015
American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc.
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Between 3% and 15% of people with cancer will
experience a bowel obstruction at some time.1,2 In
late-stage disease, when surgical and anti-cancer thera-
pies are exhausted, mean survival after the diagnosisAddress correspondence to: David C. Currow, FRACP, Disci-
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When a patient has poor performance status and anti-
cancer therapies are not an option, even minimally
invasive surgery is unlikely to improve outcomes for
someone with a malignant bowel obstruction.3 Poor
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obstruction, hypoalbuminemia, and leukocytosis.3
Therapies such as continuous nasogastric suction
and IV fluids used in the acute care setting may, on
occasion, be appropriate while an initial assessment
is taking place but are rarely a long-term option.
Malignant bowel obstructions may cause vomiting,
abdominal distension, and colicky or constant abdom-
inal pain depending, in part, on the level(s) of the
obstruction. Therapy for inoperable malignant bowel
obstruction aims to lessen symptoms: vomiting
(reducing frequency and volume by reducing gut se-
cretions) and pain (opioids for constant pain and an-
tispasmodics for colicky pain).1
There is neither standard clinical approach nor
registered medication to treat people with inoperable
malignant bowel obstructions. Two Cochrane reviews
were unable to find quality studies to help inform sur-
gical practice.4,5 A Cochrane review showed a trend fa-
voring dexamethasone over placebo in resolving
obstructions.6 More recent data suggest that steroids
independently may improve the outcome for people
treated with octreotide.7 A meta-analysis demonstrated
superiority of ranitidine over other agents, including
proton pump inhibitors, in decreasing the volume of
upper gut secretions.8 These two therapies, therefore,
were included in both arms as standard therapies.
Somatostatin has a complex action, with roles as
hormone, paracrine factor, and neurotransmitter in
the upper gut.9 Octreotide, as a somatostatin
analogue, has the theoretical potential to reduce
symptoms in malignant bowel obstruction.
In the setting of malignant bowel obstruction, with
no local or systemic disease-modifying treatments as
immediate options, five controlled trials have now
been reported, with the larger two studies using lan-
reotide (n ¼ 80)10 or lanreotide with octreotide cover
for the first six days (which only recruited 64 of its in-
tended 102 participants).11 Findings from these
studies did not support the use of somatostatin ana-
logues, whereas three studies of octreotide 300 mg/
day (n ¼ 15, 17, and 68) appeared to show
benefit.12e14 More recent open-label, single-arm, un-
controlled studies appear to show overwhelming ben-
efits for octreotide in symptomatic bowel obstructions
in gynecologic and urologic cancers (n ¼ 27, 22, and
14).7,15,16 There has been no unified approach to
the standard therapies that should be used in such
studies, the dose of octreotide, or the primary end
points; however, previous studies have helped to
inform the design and analyses of this current prag-
matic study.17
The aim of this study was to evaluate the net effect
of adding octreotide or placebo to standardized ther-
apies administered to all participants on the number
of days free of vomiting for populations presentingwith vomiting and an inoperable bowel obstruction
secondary to cancer or its treatment, where anti-
cancer therapies including surgery were not immedi-
ately indicated. The null hypothesis was that there
was no difference in the number of days free of vom-
iting between arms.Methods
Development, Ethics, Consent, and Monitoring
The study was reviewed by an internal peer-review
scientific committee with input from the Australian
Therapeutic Goods Administration and the Pharma-
ceutical Benefits Branch of the Department of
Health. The study was overseen by an independent
Data Safety Monitoring Committee and approved by
each site’s human research ethics committee. Partici-
pants provided written informed consent. People with
a previous bowel obstruction that had resolved or who
had known widespread peritoneal carcinomatosis
were eligible to provide advanced consent so that, if
in the future they experienced bowel obstruction
because of cancer or its treatments, after assessment
they could immediately commence the study proto-
col. Participants were identified by a range of clini-
cians including those in emergency, surgical,
general medicine, and oncology departments and
palliative care services in participating institutions
and their associated community teams. Once identi-
fied, consent was obtained and follow-up provided
by trained palliative care research nurses. The trial
was registered before the first recruitment
(ACTRN12608000211369).
Study Setting
The study was conducted in 12 palliative care service
networks across Australia, as part of the Australian
Government-funded national Palliative Care Clinical
Studies Collaborative. The study recruited from
August 2008 to May 2012.
Eligibility Criteria
People with vomiting secondary to a malignant
bowel obstruction where surgery or further anti-
cancer therapies were not immediately appropriate
were eligible (Table 1). Bowel obstruction was diag-
nosed on clinical grounds by two independent medi-
cal practitioners. Consultations with the treating
oncologists ensured specific anti-cancer therapies
were not immediately indicated.
People with calculated creatinine clearance
<10 mL/minute,18 severe cirrhosis, or a venting gas-
trostomy or jejunostomy were excluded. Patients with
nasogastric tubes in situ were eligible only if they
continued to vomit.
Table 1
Eligibility Criteria for the Phase III Study of Octreotide
and Placebo for the Relief of Vomiting in Inoperable
Malignant Bowel Obstruction
Inclusion criteria
 Age >18 years
 Advanced cancer
 Disease-modifying therapy (surgery, chemotherapy, radiotherapy,
hormone therapy, biological/targeted therapies) is deemed by
relevant practitioners unlikely to change the bowel obstruction
 Presents with clinically confirmed bowel obstruction at any level
with vomiting that precipitates a hospital admission or change in
clinical care
 Deemed by two consultant-level medical practitioners that this
person has a bowel obstruction (partial or complete) for which
immediate surgery is not indicated
 Participant is capable of completing assessments and complying
with the study procedures
 Participant is able to give fully informed written consent
 Not currently on octreotide
Exclusion criteria
 Previous adverse reaction to any of the study medications
 Australia-modified Karnofsky Performance Score less than 30 at
the beginning of the study
 Participants who have participated in a clinical study of a new
chemical entity within the month before study entry
 Calculated creatinine clearance <10 mL/minute
 Documented clinically significant cirrhosis
 Venting or feeding gastrostomy or jejunostomy
Table 2
Symptom Control Measures During the Study
Pain
Hyoscine butylbromide (Buscopan) 20 mg bolus subcutaneously
each hour could be administered at the discretion of the
treating clinician for colicky or uncontrolled pain up to
maximum of 120 mg/24 hours.
If necessary, an opioid may be administered according to local
protocol for pain unrelieved by hyoscine butylbromide
Nausea
Uncontrolled nausea should be treated with haloperidol as the
medication of choice according to local protocols.
Metoclopramide and domperidone are to be avoided. 5HT3
antagonists may be considered.
Vomiting
Uncontrolled vomiting is treated with
1. Push doses of hyoscine butylbromide up to 120 mg/24 hours by
infusion or repeated bolus subcutaneously.
2. Insertion of a nasogastric tube to decompress the upper
gastrointestinal tract may be an option. This will be regarded as a
treatment failure for study outcomes.
3. A trial of metoclopramide may be considered if it is part of a local
protocol, with close supervision of the site investigator
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This was a pragmatic, multisite, fixed-dose, parallel-
arm, double-blind, block-randomized, placebo-
controlled trial of the addition of a subcutaneous
infusion of octreotide (600 mg/24 hours) compared
with standardized therapies (regular parenteral dexa-
methasone [8mg/day], ranitidine [200mg/24 hours],
and hydration [10e20 mL/kg/day unless overtly de-
hydrated at study entry]).19,20 Hydration practices
differ greatly between participating centers and, in
the absence of a gold standard, the study sought to
standardize therapy. The ‘‘as-needed’’ therapies for ex-
pected symptoms also were standardized in this study:
parenteral opioids for pain, hyoscine butylbromide for
colicky pain, and haloperidol for nausea.21
Randomization and Blinding
Randomization schedules were developed for each
site using random number tables, generated centrally.
Participants were randomized in blocks of four by site
in a 1:1 ratio. Site pharmacists who opened the treat-
ment schedules to prepare the intervention were
otherwise not involved in patient care. Syringes were
identical in volume and color. No medications could
be added to study syringes. Clinical staff, assessors,
and participants were all blinded to treatment
allocations.
Outcomes
Primary. The number of days free of vomiting as re-
ported daily by patients22 was the primary outcome,measured 72 hours after the first administration of
all study medications.
Secondary. Secondary outcomes included patient-
rated Global Impression of Change (GIC) as a sum-
mary quality-of-life measure scored between 3
(much worse) and þ3 (much better),23 the number
of patient-reported episodes of vomiting, episodes of
vomiting per day, survival, nausea (National Cancer
Institute Common Toxicity Criteria Adverse Events
[NCI CTC AE]),24 the Brief Pain Inventory (BPI),25
functional status (Australia-modified Karnofsky Perfor-
mance Status [AKPS]) scale,26 and protocol-defined
as-needed symptom control medications (hyoscine bu-
tylbromide for colicky pain, opioids for pain, haloper-
idol for nausea) (Table 2). A priori, a secondary analysis
was done to see whether any clinico-demographic fac-
tors helped to predict response to octreotide.
Treatment failure included people with persistent
vomiting, insertion of nasogastric tube or venting gas-
trostomy, or a surgical procedure. Toxicity was pro-
spectively monitored for key symptoms using the
NCI CTC AE.24
Statistical Analysis
Power Calculation and Sample Size. There is no estab-
lished gold standard for assessing the outcomes of
treatment of malignant bowel obstruction.27 The
number of days free of vomiting is an objective,
patient-centered measure. A minimally significant
difference in days free of vomiting between arms
was, a priori, set at 17% to power the study, reflecting
consideration of what would be required to demon-
strate net benefit of octreotide.28 Sample size was
based on the Mann-Whitney U test. A total of 92 par-
ticipants (46 each arm) provided 80% power at a
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d of 0.17 from both groups having the same number of
days free of vomiting.
Analysis. The primary analysis was undertaken on an
intention-to-treat basis. Missing data were imputed us-
ing standard multiple imputation techniques with 20
resamples drawn.29 Proportions were compared using
Pearson chi-square, and means were compared
using t-tests or Mann-Whitney U tests, as appropriate.
The presence or absence and the number of episodes
of vomiting for each patient over the study were
analyzed using logistic and negative binomial regres-
sion, respectively, adjusting for baseline characteris-
tics: oral intake, opioid dose, body mass index, age,
gender, and level of bowel obstruction (gastric/gastric
outlet, small bowel/multi-level, large bowel). Longitu-
dinal analyses also were conducted using generalized
estimating equations with robust standard errors and
the appropriate link and distribution. All longitudinal
models were adjusted for day, study arm, the product
term study arm by day, gender, and age. Nausea was
modeled as an exponential distribution in two stages.
For those subjects experiencing nausea, intensity was
modeled with errors following a gamma distribution
with a log link. The presence or absence of nausea
was then modeled using a log link and binomial er-
rors. Both models included average pain as a covari-
ate. The use of hyoscine butylbromide also was
modeled using logistic regression, adjusting forFig. 1. CONSORT partiaverage pain and background opioid use. Pain was
treated as a continuous variable, and change in pain
over time was evaluated using a model with Gaussian
errors and an identity link. GIC as the summary
quality-of-life measure was treated as an ordinal vari-
able and analyzed using ordinal logistic regression
with robust standard errors and clustering over indi-
viduals. There was no evidence of violation of the pro-
portional odds assumption (using Stata’s omodel
command). Survival between groups was assessed us-
ing Cox proportional hazards modeling, adjusting
for age, gender, and AKPS scale. A check of the pro-
portional hazards assumption revealed no model
violation.
All results are reported as ratios (octreotide:place-
bo): odds ratio (OR), incidence rate ratio (IRR), or
hazards ratio (HR) with 95% CIs. A P-value less than
0.05 (two-tailed) was accepted as statistically signifi-
cant. All analyses were conducted using Stata 12.1
(StataCorp LP, College Station, TX).Results
The CONSORT participant flow is outlined in
Figure 1. The study recruited to its intended cohort
(Table 3). No person required dose adjustment for
renal failure. Sixty-four people provided advanced
consent; of whom, 21 were randomized. No partici-
pant had his/her therapy unblinded. Six participantscipant flow diagram.
Table 3
Baseline Characteristics of Study Participants
Baseline Characteristics Octreotide Placebo
Age (yrs), mean (SD) 62.9 (13.6) 66.3 (12.2)
Gender (female), n/N (%) 47/52 (90.4) 38/54 (70.4)
Body mass index, mean (SD) 24.0 (5.9) 24.8 (6.4)
Functional status,a median
(interquartile range)
50 (40e60) 50 (40e60)
Pain score,b median (LQeUQ) 3 (1e5) 4 (1.5e5)
Nausea,c median (LQeUQ) 2 (1e2) 1 (1e2)
Level of bowel obstruction
Gastric outlet/duodenal 9 5
Small bowel/multi-level 34 34
Large bowel 3 2
Indeterminate 8 11
LQ ¼ lower quartile; UQ ¼ upper quartile.
aMeasured using the Australia-modified Karnofsky Performance Status Scale.
bMeasured using the Brief Pain Inventory numerical rating scale (0e10)
where 0 represents ‘‘no pain’’ and 10 indicates ‘‘pain as bad as you can
imagine.’’
cMeasured using a numerical rating scale (0e10) where 0 represents no symp-
tom and 10 represents worse possible symptom.
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protocol violations (continued intake of solid food at
randomization).Primary Outcome
We recorded data at the end of Days 1, 2, and 3 on
50, 46, and 42 and 49, 47, and 45 subjects in the pla-
cebo and octreotide arms, respectively (Fig. 1). For
the primary outcome, there was no statistically signifi-
cant difference in the 1) number of days free of vom-
iting between groups (P ¼ 0.71; Fig. 2) and 2) total
number of people free of vomiting for all 72 hours
(octreotide, n ¼ 17 and placebo, n ¼ 14; P ¼ 0.67)
and mean (SD) number of days free of vomiting in
each group (1.87 [1.10], octreotide and 1.69 [1.15],
placebo; P ¼ 0.47). No Grade 3 or 4 toxicities
occurred.Fig. 2. Number of days free of vomiting between groups. P-valu
*Any people in these columns had vomiting on each of the th
no vomiting during the study.Secondary Outcomes
Both groups demonstrated a significant drop in the
mean unadjusted number of vomiting episodes be-
tween baseline and Day 1 (Fig. 3). An adjusted multi-
variate regression analysis of the incidence of vomiting
over the duration of the study showed that the octreo-
tide group experienced a reduction in the number of
episodes of vomiting compared with the placebo
group (IRR ¼ 0.40; 95% CI: 0.19e0.86; P ¼ 0.019).
At 72 hours, 31 of 42 (74%, octreotide) and 31 of 37
(84%, placebo) rated their GIC >0. Both groups were
likely to report a positive daily change in outlook
(OR ¼ 1.8; 95% CI: 1.39e2.36; P < 0.001), but there
was no difference between the groups (P > 0.75).
Neither the presence of nausea (P ¼ 0.37) nor the in-
tensity of nausea (numerical rating scale; P > 0.36)
was different between groups on any day. Average
baseline pain scores in both groups were 5.7 on the
BPI, with no difference in pain between groups on
any day. Both groups experienced slight reductions
in daily pain scores (approximately 0.25 points).
There was no difference in survival between groups
at last census date (HR ¼ 1.24; 95% CI: 0.81e1.92;
P ¼ 0.33).
Compared with placebo, people in the octreotide
arm were 2.02 times more likely to be administered hy-
oscine butylbromide each day (P ¼ 0.004). By study
end, the OR between groups rose to 3.24 (95% CI:
1.06e9.96; P ¼ 0.041). The average number of
doses/participant/group at study end was 0.51 (oc-
treotide) and 0.17 (placebo).
No clinico-demographic factors identified charac-
teristics of people more likely to have a clinical
response to octreotide in the symptomatic treatment
of vomiting secondary to bowel obstruction from can-
cer or its treatments.e for difference in medians from the Mann-Whitney U test.
ree days of the study. **Any people in these columns had
Fig. 3. Mean unadjusted number of vomiting episodes between baseline and Day 1. P-value for difference between groups and
error bars are 95% CI.
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After randomization, 19 participants did not com-
plete the study: seven before medications were admin-
istered (octreotide n ¼ 3; placebo n ¼ 4) and 12 after
(octreotide n ¼ 4; placebo n ¼ 8). No withdrawal was
the result of toxicity (Fig. 1). None of the participants
had surgery or a venting gastrostomy inserted. Three
people required a nasogastric tube (octreotide
n ¼ 2; placebo n ¼ 1).Discussion
This rigorously designed and adequately powered
study is the largest trial of somatostatin analogues
completed internationally to date for this indication,
having recruited to its planned cohort. The study stan-
dardized all therapies for both arms (with the excep-
tion of octreotide or normal saline) from currently
available evidence and was conducted across a range
of clinical settings (inpatient, consultative, and com-
munity), reflecting hospice/palliative care/oncology
practices. The number of days free of vomiting is an
objective, patient-centered primary outcome.
For a population presenting with vomiting, with no
further anti-cancer treatment immediately indicated
and an inoperable bowel obstruction, there was no sta-
tistically significant benefit in adding octreotide to
standardized therapies on days free of vomiting,
nausea, or pain. Other secondary outcomes (pres-
ence/absence and incidence of vomiting daily; num-
ber of episodes of vomiting) were not significantly
different between groups and confirmed the magni-
tude and direction of the primary findings, but the
study was not powered for secondary end points.
Planned analyses found no obvious subgroup of par-
ticipants who predictably responded to octreotide on
which to focus future research. These findings are inkeeping with two of the three largest studies of so-
matostatin analogues to date.10,11,14
Octreotide was well tolerated. There may have been
more colicky pain, greater severity, or both in the oc-
treotide group, given greater use of hyoscine butylbro-
mide for colicky pain. This may be a result of reduced
transit times from the stomach to cecum with octreo-
tide, given that most people had small bowel involved
in their obstruction.30 Hisanaga et al.31 noted in a pro-
spective study of 46 similar patients that only two
symptoms did not improve on octreotide: the number
of vomiting episodes and abdominal pain in the first
four days of treatment. Mystakidou et al.14 also re-
ported no change in pain at Days 3 and 6.
The use of a placebo arm is important as it reflects
the effects of the standardized therapies received in
both arms and isolates the specific additional benefits
of octreotide in this clinical setting, given that in some
people, bowel obstruction resolves spontaneously with
conservative measures.1,32 Studies without a control
arm using symptom control as the primary outcome
are unreliable in defining the net benefit of an
intervention.33
Octreotide is relatively expensive (A$82 daily) at this
dose. This cost needs to be considered against the net
clinical benefit from its use.34 Treatment cost differen-
tials were considered when choosing the minimum
clinically meaningful difference in this study. The find-
ings suggest no incremental value from octreotide.Strengths
This study standardized supportive care in both
arms using the best available evidence and then ran-
domized to the intervention or placebo. The study
was conducted across a range of clinical practices re-
flecting the patients seen in hospice/palliative care/
oncology settings, enhancing external validity. The
820 Vol. 49 No. 5 May 2015Currow et al.primary outcome, days free of vomiting, is an objec-
tive, patient-centered measure reflecting the needs
of people at the end of life. The chosen dose of oc-
treotide was consistent with that of the other
controlled trials.10e14,31 Secondary measures also
reflect patient-centered outcomesdvomiting, nausea,
and pain. Symptom scores were collected by actively
seeking participant responses using standardized in-
struments validated in this patient population. Missing
data and attrition rates were relatively low for a study
in such a frail population.
Limitations
Other studies have followed people longer than the
72 hour primary census point in this present study.
Choosing a period long enough to be meaningful
and short enough to optimize participant retention is
a key balance in hospice/palliative care studies.17
Benefit from a medication to reduce vomiting should
be seen within three days, even if maximal benefit
takes longer. Whether higher doses of octreotide
have greater benefit could be explored in future
work, but the chosen dose was double the dose used
in two of the three studies available at the time of
design and the same as the dose in the third study.12e14
The conservative intention-to-treat analysis is sup-
ported by the secondary analyses exploring the pres-
ence/absence and incidence of vomiting daily and
the number of episodes of vomiting during the study,
which confirmed the primary findings in direction
and magnitude.
Implications for Clinical Practice
This study does not support the routine use of oc-
treotide in addition to ranitidine and dexamethasone
for the symptomatic treatment of inoperable malig-
nant bowel obstruction. There may be benefit in sub-
populations, but their characteristics were not evident
from attempts to identify such populations across the
patients recruited in this study. Octreotide was well
tolerated, but the higher likelihood of hyoscine butyl-
bromide administration for colicky pain suggests that
there may be a symptomatic burden from octreotide
in some patients.
Future Research Directions
A key question is the relative contribution of dexa-
methasone and ranitidine to any change seen in vom-
iting. This needs to be elucidated in future studies.
This study also opens the way to future work
including formal evaluation of ranitidine or dexa-
methasone or both or neither in this clinical setting
and recruitment of an enriched cohort where a combi-
nation of ranitidine and dexamethasone has failed to
control vomiting at 72 hours. The choice betweenoctreotide or a newer somatostatin analogue such as
pasireotide needs to be carefully considered in future
studies, given that the effect on the volume of upper
gastrointestinal secretions or gut motility may differ
between both compounds. A better understanding of
the characteristics of people most likely to respond
symptomatically to a somatostatin analogue also is an
important outcome of future controlled clinical trials.Disclosures and Acknowledgments
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